SNOA · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$1.11-4.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $7.2M | $5.6M | +28.02% |
| Profit | -$66K | -$534K | +87.64% |
| Profit per share | -$0.01 | -$0.32 | +96.88% |
| Free Cash Flow | -$778K | -$645K | -20.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Sonoma Pharmaceuticals, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“A record high quarterly revenue for the company of $4.9 million, along with higher gross profitability enabled us to achieve a two-year low in EBITDA loss, which is operating loss minus non-cash expenses,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Sonoma Pharmaceuticals, Inc.’s Item 2.02 8-K filed November 8, 2018; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.